{24 (drospirenone 4 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack [Slynd... — RxCUI 2171002
RxNorm drug concept · Brand name pack
RxCUI 2171002
Brand name pack · BPCK
● Current RxNorm concept 1 FDA product
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2171002
Official name{24 (drospirenone 4 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack [Slynd]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known asSlynd 28 Day Pack
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)243,138 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
🕸️ Concept Web — How {24 (drospirenone 4 MG Oral Tablet) / 4 (inert i... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
{24 (drospirenone 4 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack [Slynd]
RxCUI 2171002 Brand name pack · BPCK
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Drospirenone
11636IN -
Inert ingredients
748794IN
-
Drospirenone
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Drospirenone Oral Tablet
2170999SCDF -
Inert ingredients Oral Tablet
748796SCDF -
Drospirenone Oral Product
2170997SCDG -
Drospirenone Pill
2170998SCDG -
Inert ingredients Oral Product
1156911SCDG -
Inert ingredients Pill
1156912SCDG -
Pack
746839DF -
Oral Product
1151131DFG - +1 more in this family
-
Drospirenone Oral Tablet
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Drospirenone 4 MG Oral Tablet
2171000SCD -
Inert ingredients 1 MG Oral Tablet
748797SCD -
Drospirenone 4 MG
2170996SCDC -
Inert ingredients 1 MG
748795SCDC
-
Drospirenone 4 MG Oral Tablet
-
Packs 1
Fixed collections of drugs packaged and sold together, like dose packs.
Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Drospirenone 4 MG Oral Tablet
SCD · 2171000 -
Inert ingredients 1 MG Oral Tablet
SCD · 748797 -
{24 (drospirenone 4 MG Oral Tablet) / 4 (inert ingredients 1 MG Oral Tablet) } Pack
GPCK · 2171001 -
Drospirenone 4 MG
SCDC · 2170996 -
Inert ingredients 1 MG
SCDC · 748795 -
Drospirenone Oral Tablet
SCDF · 2170999 -
Inert ingredients Oral Tablet
SCDF · 748796 -
Drospirenone Oral Product
SCDG · 2170997 -
Drospirenone Pill
SCDG · 2170998 -
Inert ingredients Oral Product
SCDG · 1156911
📦 FDA Products & Package NDCs
1 product · 2 package NDCs
2 package NDCs map to RxCUI 2171002 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00642-7470-01 | 1 KIT in 1 CARTON (0642-7470-01) * 24 TABLET, FILM COATED... | SLYND | Exeltis USA, Inc. | 2019-09-01 |
| 00642-7470-02 | 1 KIT in 1 CARTON (0642-7470-02) * 24 TABLET, FILM COATED... | SLYND | Exeltis USA, Inc. | 2019-09-01 |
Observed labelers:
Exeltis USA, Inc. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.